INT104668

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 27
Total Number 32
Disease Relevance 17.18
Pain Relevance 4.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plat) extracellular space (Plat) extracellular region (Plat)
cytoplasm (Plat)
Anatomy Link Frequency
astrocytes 4
brain 2
endothelial cells 1
pericytes 1
ear 1
Plat (Mus musculus)
Pain Link Frequency Relevance Heat
Hippocampus 12 99.84 Very High Very High Very High
Inflammation 174 99.64 Very High Very High Very High
cva 63 99.64 Very High Very High Very High
Inflammatory response 9 98.58 Very High Very High Very High
Multiple sclerosis 21 98.28 Very High Very High Very High
Morphine 5 98.00 Very High Very High Very High
Central nervous system 27 97.56 Very High Very High Very High
cINOD 9 96.68 Very High Very High Very High
Dopamine 1 95.72 Very High Very High Very High
Pain threshold 3 92.00 High High
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 68 100.00 Very High Very High Very High
INFLAMMATION 186 99.64 Very High Very High Very High
Hemorrhage 22 99.64 Very High Very High Very High
Injury 55 99.20 Very High Very High Very High
Multiple Sclerosis 12 98.80 Very High Very High Very High
Demyelinating Disease 27 98.28 Very High Very High Very High
Coronary Artery Disease 8 98.04 Very High Very High Very High
Disease 72 97.92 Very High Very High Very High
Stroke 147 97.88 Very High Very High Very High
Neurological Disease 2 96.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In brain, tissue plasminogen activator (tPA) expression in astrocytes is the primary source of plasminogen activator and PAI-1 is the dominant inhibitor of tPA [21].
Negative_regulation (inhibitor) of tPA in astrocytes
1) Confidence 0.49 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2815778 Disease Relevance 0.48 Pain Relevance 0.18
A temporally restricted attenuation of tPA activity could have therapeutic potential in the management of MS.
Negative_regulation (attenuation) of tPA associated with multiple sclerosis
2) Confidence 0.43 Published 2002 Journal J. Neurosci. Section Abstract Doc Link 12486171 Disease Relevance 1.34 Pain Relevance 0.42
To explore the role of tPA in this disease as a model for MS, we have examined the EAE course and expression of histopathological markers in mice lacking tPA (tPA(-/-)).
Negative_regulation (lacking) of tPA associated with multiple sclerosis and disease
3) Confidence 0.43 Published 2002 Journal J. Neurosci. Section Abstract Doc Link 12486171 Disease Relevance 1.55 Pain Relevance 0.50
To explore the role of tPA in this disease as a model for MS, we have examined the EAE course and expression of histopathological markers in mice lacking tPA (tPA(-/-)).
Negative_regulation (lacking) of tPA associated with multiple sclerosis and disease
4) Confidence 0.43 Published 2002 Journal J. Neurosci. Section Abstract Doc Link 12486171 Disease Relevance 1.55 Pain Relevance 0.50
Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice.
Negative_regulation (effect) of tissue-plasminogen activator in hippocampus associated with hippocampus
5) Confidence 0.43 Published 2002 Journal Neuroscience Section Title Doc Link 12182903 Disease Relevance 0.41 Pain Relevance 0.24
The beneficial effect of tPA was abolished by co-infusion of its inhibitor tPA-STOP, indicating that the facilitatory effect of tPA on learning requires a proteolytic step.
Negative_regulation (abolished) of tPA
6) Confidence 0.43 Published 2002 Journal Neuroscience Section Abstract Doc Link 12182903 Disease Relevance 0.41 Pain Relevance 0.28
The learning deficit was also partially restored by limited intrahippocampal delivery of tPA (infused for 2 h before training; P < 0.05 vs control), but not by the delivery of urokinase plasminogen activator, indicating the acute need for tPA in learning.
Negative_regulation (delivery) of tPA
7) Confidence 0.43 Published 2002 Journal Neuroscience Section Abstract Doc Link 12182903 Disease Relevance 0.45 Pain Relevance 0.28
Fig. 2a, 2b show that OGD treatment significantly decreased the tPA activity in astrocytes.
Negative_regulation (decreased) of tPA in astrocytes
8) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2815778 Disease Relevance 0 Pain Relevance 0
Therefore, any way to reduce tPA-associated blood-brain barrier (BBB) injury may extend the time window for safe and effective reperfusion therapy, and ultimately increase the overall efficacy of tPA thrombolytic therapy.
Negative_regulation (reduce) of tPA in brain associated with injury
9) Confidence 0.40 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.47 Pain Relevance 0.12
Similarly, methamphetamine-induced conditioned place preference and locomotor sensitization were reduced in tPA-/- mice.
Negative_regulation (reduced) of tPA
10) Confidence 0.37 Published 2005 Journal J. Pharmacol. Sci. Section Abstract Doc Link 15684570 Disease Relevance 0.22 Pain Relevance 0.75
A single experienced sonographer acquired images suitable for determination of IMT, TPA and TPV.


Negative_regulation (determination) of TPA
11) Confidence 0.37 Published 2006 Journal Cardiovasc Ultrasound Section Body Doc Link PMC1657034 Disease Relevance 1.05 Pain Relevance 0.07
As a member of the serpine gene family, PAI-1 is the major inhibitor of tPA [21], and is largely produced by reactive astrocytes in the CNS after stroke [65], [66].
Negative_regulation (inhibitor) of tPA in astrocytes associated with stroke and central nervous system
12) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2815778 Disease Relevance 0.42 Pain Relevance 0.09
To further investigate the mechanism of cilostazol to beneficial effect, we also performed an in vitro study with tPA and a phosphodiesterase-III inhibitor in human brain microvascular endothelial cells, pericytes, and astrocytes.
Negative_regulation (inhibitor) of tPA in pericytes
13) Confidence 0.35 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2997776 Disease Relevance 0.39 Pain Relevance 0.13
Interestingly, delayed tPA at 6 h markedly diminished claudin-5 levels in brain tissue.
Negative_regulation (delayed) of tPA in brain
14) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.30 Pain Relevance 0.03
The MMP-9 activity was significantly decreased with tPA plus cilostazol at 6 h.
Negative_regulation (decreased) of tPA
15) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997776 Disease Relevance 0.82 Pain Relevance 0.20
All treatments significantly (P < 0.05) reduced TPA-induced irritation injury.
Negative_regulation (reduced) of TPA associated with injury
16) Confidence 0.31 Published 2010 Journal J. Agric. Food Chem. Section Abstract Doc Link 20415425 Disease Relevance 0.67 Pain Relevance 0.25
Products of arachidonic acid metabolism such as PGI2 and LTB4 increase vascular permeability leading to edema during the inflammatory response [23], and compounds inhibiting COX and LOX enzymes have been shown to inhibit TPA-induced inflammation [23].
Negative_regulation (inhibit) of TPA associated with pressure and volume under development, inflammatory response and inflammation
17) Confidence 0.19 Published 2008 Journal J Inflamm (Lond) Section Body Doc Link PMC2267461 Disease Relevance 0.96 Pain Relevance 0.35
At 24 h, all experimental groups had significantly reduced ear edema compared to TPA alone except PCE at 0.075 mg per ear and the trans-resveratrol-treated groups.
Negative_regulation (reduced) of TPA in ear associated with pressure and volume under development
18) Confidence 0.19 Published 2008 Journal J Inflamm (Lond) Section Body Doc Link PMC2267461 Disease Relevance 0.82 Pain Relevance 0
Therefore, a method is needed to reduce t-PA-induced hemorrhage and extend the therapeutic time window for safe and effective reperfusion to limit cerebral damage.
Negative_regulation (reduce) of t-PA associated with cva
19) Confidence 0.15 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 1.38 Pain Relevance 0.10
To further investigate the mechanism of cilostazol to beneficial effect, we also performed an in vitro study with tPA and a phosphodiesterase-III inhibitor in human brain microvascular endothelial cells, pericytes, and astrocytes.
Negative_regulation (inhibitor) of tPA in astrocytes
20) Confidence 0.12 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2997776 Disease Relevance 0.39 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox